Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 2/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | NEK2 | P51955 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7375459 | 0.75 | HIF1A (0.54) | HIF1ATNNI3KLMNACYP1A2MAPK1 | |
| SCHEMBL11415127 | 0.75 | HIF1A (0.54) | HIF1AEGFRCSF1RNEK2LMNA | |
| SCHEMBL7375286 | 0.75 | HSD17B10 (0.55) | HIF1ABRD4LMNACYP1A2MAPK1 | |
| SCHEMBL30925386 | 0.71 | HIF1A (0.61) | HIF1ATNNI3KLMNACYP1A2CDK2 | |
| SCHEMBL2938675 | 0.68 | AKT2 (0.70) | CDC7DBF4EGFRCSF1RNEK2 | |
| SCHEMBL5829620 | 0.68 | CDC7 (0.48) | HIF1ABRD4CDC7DBF4EGFR | |
| SCHEMBL11062732 | 0.66 | KMT2A (0.54) | LMNAMAPK1HTTRAB9AALDH1A1 | |
| SCHEMBL1060507 | 0.65 | MKNK1 (0.72) | TNNI3KEGFRLMNACYP1A2MAPK1 | |
| SCHEMBL796398 | 0.65 | CDC7 (0.72) | HIF1ACDC7DBF4EGFRCSF1R | |
| SCHEMBL5384434 | 0.65 | CDC7 (0.59) | HIF1ACDC7DBF4EGFRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009642-A1 | Methods for the synthesis of substituted purines | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2006-01-12 | — | — | US | disclosed |
| US-6949644-B2 | Methods for the synthesis of substituted purines | IRM LLC (BM) | 2005-09-27 | — | — | US | disclosed |
| EP-1529048-A4 | METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES | IRM LLC (BM) | 2005-09-14 | — | — | EP | disclosed |
| EP-1529048-A2 | METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES | IRM LLC (BM) | 2005-05-11 | — | — | EP | disclosed |
| US-20030171583-A1 | Methods for the synthesis of substituted purines | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2003-09-11 | — | — | US | disclosed |
| WO-2003031405-A2 | METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES | IRM LLC (BM) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009642-A1 | Methods for the synthesis of substituted purines | PNP, ATIC, NUDT1 | HIF1A 3946/4885TNNI3K 4440/4885BRD4 1428/4885 |
| US-20030171583-A1 | Methods for the synthesis of substituted purines | PNP, ATIC, NUDT1 | HIF1A 3943/4885TNNI3K 4424/4885BRD4 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.